Molecular Pharmaceutics · 2014 · 17 citations · 28 references
MedicineOncologyPharmacologyMetastasisMolecular ImagingMolecular OncologyMolecular Imaging In OncologyMolecular Probe DevelopmentTargeted Cancer TherapyTargeted Imaging AgentsTumor CharacterizationTumor ImagingAxl Receptor Tyrosine KinaseBifunctional ChelatorsCancer ImagingMolecular Imaging Of CancerMolecular Imaging Probe DesignMonoclonal Antibody CharacterizationMonoclonal Antibody DesignTargeted Molecular Imaging Agents
Accumulating experimental evidence indicates that overexpression of the oncogenic receptor tyrosine kinase, Axl, plays a key role in the tumorigenesis and metastasis of various types of cancer. The objective of this study is to design a novel imaging probe based on the monoclonal antibody, h173, for microPET imaging of Axl expression in human lung cancer. A bifunctional chelator, DOTA, was conjugated to h173, followed by radiolabeling with (64)Cu. The binding of DOTA-h173 to the Axl receptor was first evaluated by a cell uptake assay and flow cytometry analysis using human lung cancer cell lines. The probe (64)Cu-DOTA-h173 was further evaluated by microPET imaging, and ex vivo histology studies in the Axl-positive A549 tumors. In vitro cellular study showed that Axl probe, (64)Cu-DOTA-h173, was highly immuno-reactive with A549 cells. Western blot analysis confirmed that Axl is highly expressed in the A549 cell line. For microPET imaging, the A549 xenografts demonstrated a significantly higher (64)Cu-DOTA-h173 uptake compared to the NCI-H249 xenograft (a negative control model). Furthermore, (64)Cu-DOTA-h173 uptake in A549 is significantly higher than that of (64)Cu-DOTA-hIgG. Immuno-fluorescence staining was consistent with the in vivo micro-PET imaging results. In conclusion, (64)Cu-DOTA-h173 could be potentially used as a probe for noninvasive imaging of Axl expression, which could collect important information regarding tumor response to Axl-targeted therapeutic interventions.
28
Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu, James Greger, Hong Shi et al. · Cancer Research · 2009 · 491 citations · Full text
Medicine, Oncology, Pharmacology +17